CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS May 22, 2020 8:49pm EDT
CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population May 19, 2020 6:00am EDT
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir May 18, 2020 6:00am EDT
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19 May 15, 2020 6:00am EDT
CytoDyn Completed Submission of All Remaining Parts of Biologics License Application (“BLA”) on May 11, 2020 May 13, 2020 6:00am EDT
CytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT May 11, 2020 6:00am EDT
Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients May 07, 2020 6:18pm EDT
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients May 06, 2020 1:24am EDT
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May May 04, 2020 6:00am EDT
